5Kris MG,Hesketh PJ,Herrstedt J,et al.Consensus proposals forthe prevention of acute and delayed vomiting and nausea followinghigh-emetic-risk chemotherapy[J].Support Care Cancer,2005,13(2):85-96.
6Wong EH,Clark R,Leung E,et al.The interaction of RS 25259-197,a potent and selective antagonist,with 5-HT3 receptors,in vitro[J].BrJ Pharmacol,1995,114(4):851-859.
7Stoltz R,CyongJC,Shah A,et al.Pharmacokinetic and safety eval-uation of palonosetron,a 5-hydroxytryptamine-3 receptor antago-nist,in U.S.and Japanese healthy subjects[J].J Clin Pharmacol,2004,44(5):520-531.
8Piraccini G,Stolz R,Tei M,et al.Pharmacokinetic features of a novel5-HT 3-receptor antagonist:Palonosetron(RS-25259-197)[J].ProcAm Soc Clin Oncol,2001:400a.
9Navari RM.Palonosetron:a second generation 5-hydroxytrypta-mine 3 receptor antagonist[J].Expert Opin Drug Metab Toxicol,2009,5(12):1577-1586.
10Wren SA,Tchelitcheff P.Use of ultra-performance liquid chroma-tography in pharmaceutical development[J].J Chromatogr A,2006,1119(1):140-146.
